Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd announced the successful evaluation of its ColoSTAT® test, which demonstrates consistent performance in detecting colorectal cancer across various age groups and genders. The test shows promise for early onset cancer detection in patients under 50 years old, addressing a growing need in the healthcare industry. The company plans further studies to establish statistical significance and aims for commercial release following regulatory assessments.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on providing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden. Rhythm Biosciences collaborates with global partners to commercialize and distribute its diagnostic solutions.
Average Trading Volume: 816,738
Technical Sentiment Signal: Buy
Current Market Cap: A$31.63M
See more insights into RHY stock on TipRanks’ Stock Analysis page.